Purpose

The study medication (BAY 2315497 Injection) is a thorium-227 labeled immuno-conjugate, specific for the prostate-specific membrane antigen (PSMA), which will be evaluated in patients with metastatic castration resistant prostate cancer. In this study, this investigational medication will be administered to patients for the first time. The primary objective of the study is to define the safety and tolerability profile and Maximal Tolerated Dose (MTD) of BAY 2315497 Injection. The secondary objectives are to determine the recommended dose for further clinical development and to investigate how the study drug is distributed and cleared from the body.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Ability to understand and sign an approved informed consent form. - Male adult patients (≥ 18 years of age). - ECOG PS of 0 or 1. - Life expectancy ≥ 6 months. - Histological, pathological and/or cytological confirmation of adenocarcinoma of the prostate without small cell or neuroendocrine features. - Previous treatment with at least one novel androgen axis drug (NAAD) (e.g. enzalutamide and/or abiraterone). - Patients must have prior orchiectomy and/or ongoing androgen deprivation therapy and a castrate level of serum testosterone (<50 ng/dL or <1.7 nmol/L). - Previous treatment with at least 1, but no more than 2 previous - taxane regimens. A taxane regimen is defined as a minimum exposure of 2 cycles of a taxane. If a patient has received only 1 taxane regimen, he is eligible, if refuses to receive a second taxane regimen, or is considered unsuitable to receive a second taxane regimen (e.g. intolerance). - Documented progression of mCRPC, as defined according to the Prostate Cancer Working Group 3 (PCWG3) guidelines. - Adequate bone marrow, liver, and renal function, as assessed by the following laboratory requirements, to be conducted within 14 days before start of study drug administration: - Hemoglobin > 9.0 g/dL - Absolute neutrophil count (ANC) > 1500/mm3 - White blood cell (WBC) count > 3000/mL - Platelet count > 100,000 /mm*3 - Total bilirubin < 1,5 x upper limit of normal (ULN) (except if confirmed history of Gilbert's disease) - ALT and AST ≤ 2.5 x ULN - Serum creatinine ≤ 1.5 X ULN and glomerular filtration rate (GFR ≥ 45 mL/min/1.73 m2, according to the MDRD (Modified Diet in Renal Disease) abbreviated formula. - Patients with partners of childbearing potential must be willing to use highly effective methods of birth control for the time period between the first administration of BAY 2315497 Injection to at least 6 months after the last administration of the study drug.

Exclusion Criteria

  • Diffuse bone or bone-marrow involvement (i.e. "superscan"). - Spinal cord compression or known brain metastases. - Known incompatibility to CT/MRI, bone scan or uncontrolled pain, which results in patient's lack of compliance with the CT/MRI and bone scan required for PCWG3 tumor assessment. - Clinically significant heart disease, as evidenced by myocardial infarction, arterial thrombotic events in the past 6 months, severe or unstable angina, or uncontrolled cardiovascular history. - Patients known to be affected by genetic defects linked to radiation Hypersensitivity. - Known history of myelodysplastic syndrome (MDS) / leukemia or with features suggestive of MDS/AML at any time point. - Concurrent or active cancer within the last 2 years with a distinct primary site or histology from the cancer being evaluated in this study, with the exception of cancer types with less than 30% likelihood of recurrence. - Known allergies, hypersensitivity, or intolerance to the study drug including excipients, or to contrast agents used in the diagnostic or exploratory imaging procedures required per protocol. - Any infection of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 Grade ≥ 2. - Known human immunodeficiency virus (HIV) infection. - Patients who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment. - Serious, non-healing wound, ulcer, or bone fracture. - Any systemic anti-neoplastic therapy (e.g. chemotherapy, immunotherapy or biological therapy [including monoclonal antibodies], PARP inhibitors) within at least 30 days prior to day of randomization (except for Luteinizing Hormone-releasing Hormone [LHRH] or Gonadotropin-releasing Hormone [GnRH]). - Previous high-dose chemotherapy, needing hemopoietic stem cell rescue, is prohibited. - Prior major surgery (excluding prostatic biopsies) must be at least 12 weeks prior to study entry. - Previous treatment with therapeutic PSMA-targeted agents. - Previous treatment with radium-223 dichloride or other radiopharmaceuticals, including but not limited to strontium-89 or samarium-153. - Prior definitive radiotherapy completed less than 6 weeks before start of the study drug administration

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
BAY2315497 dose escalation
The thorium-227 dose will be escalated in a step-wise fashion to the MTD, according to a predefined dose escalation scheme. The total antibody dose of 50 mg will be evaluated first; on the basis of emerging clinical data, doses within the range of 20-100 mg may be investigated.
  • Drug: BAY2315497 Injection
    BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.
Experimental
BAY2315497 dose expansion:Dose regimen 1
The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY2315497 Injection, observed in the course of the dose escalation.
  • Drug: BAY2315497 Injection
    BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.
Experimental
BAY2315497 dose expansion:Dose regimen 2
The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY2315497 Injection, observed in the course of the dose escalation.
  • Drug: BAY2315497 Injection
    BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.

Recruiting Locations

Tulane Medical Center
New Orleans, Louisiana 70112

More Details

Status
Recruiting
Sponsor
Bayer

Study Contact

Bayer Clinical Trials Contact
(+)1-888-84 22937
clinical-trials-contact@bayer.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.